PY 2026 eCQM Colorectal Cancer Screening Measure

XMLWordPrintable

    • Type: EC eCQMs - Eligible Clinicians
    • Resolution: Answered
    • Priority: Moderate
    • Component/s: None
    • None
    • Rashaan Byers
    • 281-979-8887
    • Houston Methodist Coordinated Care
    • Hide
      Thank you for your inquiry regarding CMS130v14 (2026 Performance Period). This measure is based on the guidelines from the U.S. Preventive Services Task Force (USPSTF), which does not recognize the CRC blood test as an acceptable option for meeting the measure's criteria. To meet the numerator requirements, applicable screenings include Fecal Occult Blood Test, Stool DNA with Fecal Immunochemical Test (FIT), Flexible Sigmoidoscopy, CT Colonography, or a colonoscopy. Clinically equivalent services may be mapped to the codes used in a measure's value sets to satisfy a value set requirement. If mapping is conducted, you should maintain documentation in case of a CMS audit. Please review the measure specification for further details about measure requirements: https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS130-v14.0.000-QDM.html.
      Show
      Thank you for your inquiry regarding CMS130v14 (2026 Performance Period). This measure is based on the guidelines from the U.S. Preventive Services Task Force (USPSTF), which does not recognize the CRC blood test as an acceptable option for meeting the measure's criteria. To meet the numerator requirements, applicable screenings include Fecal Occult Blood Test, Stool DNA with Fecal Immunochemical Test (FIT), Flexible Sigmoidoscopy, CT Colonography, or a colonoscopy. Clinically equivalent services may be mapped to the codes used in a measure's value sets to satisfy a value set requirement. If mapping is conducted, you should maintain documentation in case of a CMS audit. Please review the measure specification for further details about measure requirements: https://ecqi.healthit.gov/sites/default/files/ecqm/measures/CMS130-v14.0.000-QDM.html .
    • CMS0130v14
    • Colorectal Cancer Screening is a MSSP quality reporting measure for PY2026 and I need to know will this test satisfy the Colorectal Cancer Screening Measure.

      Hello,

      Will the Guardant Shield blood-based colorectal cancer screening test satisfy the eCQM Colorectal Cancer Screening measure for PY 2026? This test currently is not listed in the measure specifications as an acceptable test to meet the metric but wanted to clarify since it is a new FDA approved colorectal cancer screening test. Please advise.

      Thanks

            Assignee:
            AIR EC eCQM Team
            Reporter:
            Rashaan Byers
            Votes:
            0 Vote for this issue
            Watchers:
            2 Start watching this issue

              Created:
              Updated:
              Resolved:
              Solution Posted On: